REYON Pharmaceutical Valuation

Is A102460 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A102460 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A102460 (₩14330) is trading above our estimate of fair value (₩2709.36)

Significantly Below Fair Value: A102460 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A102460?

Key metric: As A102460 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A102460. This is calculated by dividing A102460's market cap by their current revenue.
What is A102460's PS Ratio?
PS Ratio	1.8x
Sales	₩149.84b
Market Cap	₩258.61b

A102460 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.7x
Enterprise Value/EBITDA	49.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A102460's PS Ratio compare to its peers?

The above table shows the PS ratio for A102460 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.2x
A058820 CMG Pharmaceutical	2.9x	n/a	₩271.1b
A001630 Chong Kun Dang Holdings	0.3x	5.0%	₩244.2b
A216080 JETEMA	5.5x	n/a	₩365.9b
A009290 Kwang Dong Pharmaceutical	0.1x	n/a	₩224.9b
A102460 REYON Pharmaceutical	1.8x	n/a	₩258.6b

Price-To-Sales vs Peers: A102460 is good value based on its Price-To-Sales Ratio (1.8x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does A102460's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 Companies	Price / Sales	Estimated Growth	Market Cap
A009290 Kwang Dong Pharmaceutical	0.1x	n/a	US$161.67m
A002620 Jeil Pharma Holdings	0.2x	n/a	US$94.48m
A000230 Ildong Holdings	0.1x	n/a	US$56.43m

No more companies available in this PS range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A102460 is expensive based on its Price-To-Sales Ratio (1.8x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A102460's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A102460 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A102460's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

J2KBIO

₩54.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,830.00

6.0%

n/a

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,000.00

-3.4%

75.9%

Dong-A ST

₩544.1b

Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

A170900

₩62,300.00

-2.0%

8.6%